Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats

Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats

© 2017 John Wiley & Sons Ltd Aims: Comparative efficacy between fibroblast growth factor 21 (FGF21) and vildagliptin on metabolic regulation, cardiac mitochondrial function, heart rate variability (HRV), and left ventricular (LV) function is not known. We hypothesized that FGF21 and vildaglipt...

Saved in:

書目詳細資料
Main Authors:	Tanajak P., Sa-nguanmoo P., Apaijai N., Wang X., Liang G., Li X., Jiang C., Chattipakorn S., Chattipakorn N.
格式:	雜誌
出版:	2017
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85023613689&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40215
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	Chiang Mai University

相似書籍

Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats
由: Pongpan Tanajak, et al.
出版: (2018)

Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats
由: Pongpan Tanajak, et al.
出版: (2018)

Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury
由: Chinda K., et al.
出版: (2014)

Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury
由: Chinda K., et al.
出版: (2014)

Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury
由: Kroekkiat Chinda, et al.
出版: (2018)

Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury
由: Kroekkiat Chinda, et al.
出版: (2018)

Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance
由: Jitjiroj Ittichaicharoen, et al.
出版: (2018)

Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance
由: Jitjiroj Ittichaicharoen, et al.
出版: (2018)

Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction
由: Apaijai N., et al.
出版: (2017)

Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats
由: Pintana H., et al.
出版: (2017)

Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control
由: Chattipakorn N., et al.
出版: (2017)

Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction
由: Nattayaporn Apaijai, et al.
出版: (2018)

Energy restriction combined with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in obese male rats
由: Hiranya Pintana, et al.
出版: (2018)

Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control
由: Nipon Chattipakorn, et al.
出版: (2018)

Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction
由: Inthachai T., et al.
出版: (2015)

Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction
由: Inthachai T., et al.
出版: (2015)

Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, Improves Trabecular Bone Mineral Density and Microstructure in Obese, Insulin-Resistant, Pre-diabetic Rats
由: Narattaphol Charoenphandhu, et al.
出版: (2018)

Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, Improves Trabecular Bone Mineral Density and Microstructure in Obese, Insulin-Resistant, Pre-diabetic Rats
由: Narattaphol Charoenphandhu, et al.
出版: (2019)

Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction
由: Tharnwimol Inthachai, et al.
出版: (2018)

Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction
由: Tharnwimol Inthachai, et al.
出版: (2018)

Combined dipeptidyl peptidase-4 inhibitor with low-dose testosterone exerts greater efficacy than monotherapy on improving brain function in orchiectomized obese rats
由: Puntarik Keawtep, et al.
出版: (2019)

Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart
由: Chinda K., et al.
出版: (2014)

Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart
由: Chinda K., et al.
出版: (2014)

Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats
由: Hiranya Pintana, et al.
出版: (2018)

Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats
由: Hiranya Pintana, et al.
出版: (2018)

Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart
由: Kroekkiat Chinda, et al.
出版: (2018)

Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart
由: Kroekkiat Chinda, et al.
出版: (2018)

Potential roles of fibroblast growth factor 21 in the brain
由: Sa-nguanmoo P., et al.
出版: (2017)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
由: Watshara Shoombuatong, et al.
出版: (2015)

Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor
由: Jitjiroj Ittichaicharoen, et al.
出版: (2018)

Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor
由: Jitjiroj Ittichaicharoen, et al.
出版: (2018)

Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats
由: Tanajak P., et al.
出版: (2017)

Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats
由: Tanajak P., et al.
出版: (2017)

Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats
由: P. Tanajak, et al.
出版: (2018)

Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats
由: Charoenphandhu N., et al.
出版: (2017)

Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
由: J. Kongwatcharapong, et al.
出版: (2018)

Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
由: Kongwatcharapong J., et al.
出版: (2017)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
由: Permsuwan U., et al.
出版: (2017)

Potential roles of fibroblast growth factor 21 in the brain
由: Piangkwan Sa-nguanmoo, et al.
出版: (2018)

Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
由: Sivasinprasasn S., et al.
出版: (2017)